Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antagonist activity at NR2C2 (unknown origin) at 1 uM
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Antagonist activity at NR2C1 (unknown origin) at 1 uM
Inverse agonist activity at NR2C2 (unknown origin) at 1 uM
Inverse agonist activity at NR2C1 (unknown origin) at 1 uM
Agonist activity at NR2C2 (unknown origin) at 1 uM
Agonist activity at NR2C1 (unknown origin) at 1 uM
Inhibition of TAK1 (unknown origin) assessed as remaining activity at 10 uM relative to control
Methods for Evaluating TAK1 Modulators from US Patent US20240116893: "Compounds for Disease Treatment"
Assay data:8 Active, 8 Activity ≤ 1 µM, 8 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of TAK (unknown origin)
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of TAK/TAB (unknown origin)
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of recombinant human N-terminal GST-tagged TAK1 (1 to 303 residues)/TAB1 (437 to end residues) expressed in baculovirus infected Sf9 insect cells using myelin basic protein as substrate preincubated for 10 mins followed by ATP addition and measured after 45 mins by kinase-glo luminescence assay
Assay data:12 Active, 25 Activity ≤ 1 µM, 36 Tested
Inhibition of human TAK1 in presence of ATP by radiometric assay
Caliper Kinase Assay from US Patent US10676460: "Quinazolines as potassium ion channel inhibitors"
Assay data:1 Active, 1 Activity ≤ 1 µM, 3 Tested
In Vitro Activity Assay from US Patent US10633348: "Methods to treat lymphoplasmacytic lymphoma"
Assay data:14 Active, 12 Activity ≤ 1 µM, 16 Tested
In Vitro Activity Assay from US Patent US10597387: "Methods to treat lymphoplasmacytic lymphoma"
Binding Assay from US Patent US10000483: "Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof"
Assay data:27 Active, 1 Activity ≤ 1 nM, 26 Activity ≤ 1 µM, 27 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Inhibition Assay from US Patent US9908872: "Methods to treat lymphoplasmacytic lymphoma"
Caliper Kinase Assay from US Patent US10214511: "Quinazolines as potassium ion channel inhibitors"
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of human TAK1B in human A549 cells assessed as suppression of TNF-alpha induced TAK1 phosphorylation at 0.5 to 5 uM pretreated with compounds for 24 hrs followed by TNF-alpha stimulation for 10 mins by Western blot analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of human TAK1 in human A549 cells assessed as suppression of TNF-alpha induced TAK1 expression at 0.5 to 5 uM pretreated with compounds for 24 hrs followed by TNF-alpha stimulation for 10 mins by Western blot analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on